Successful New Treatment For Hodgkin's Lymphoma, Reduces Long-term Risks


  Friday 17 July 2009 - 00:59:21

New research led by Cindy Schwartz, MD, of Hasbro Children's Hospital has identified a new chemotherapy regimen for pediatric Hodgkin lymphoma (HL) patients. The new treatment enhances efficacy through dose-dense drug delivery while simultaneously reducing the long-term risks presented by high cumulative dose chemotherapy. Schwartz and the researchers of the Children's Oncology Group have published their findings in the journal Blood (posted in an online first edition).

The Children's Oncology Group's Hodgkin Lymphoma Committee, led by Schwartz, director of pediatric hematology/oncology at Hasbro Children's Hospital, recognized that treatment for HL in the United States was not being treated with the most modern treatment models, in large part because it was one of the first malignancies for which a curative chemotherapy regimen was developed.

Schwartz says, "For decades, the chemotherapy regimens known as MOPP and ABVD had been the standard treatment options for these patients. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy and cardiopulmonary toxicity. With the new treatment paradigm we've developed, in essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients."

The group designed a new chemotherapy treatment known as ABVE-PC, combining six different drugs into one "dose-dense" regimen that could limit the cumulative doses of each drug below the recognized thresholds known for resulting in long-term toxicity. Their goal was to reach a rapid early response (RER) in order to further reduce cumulative therapy and to thereby increase event-free survival (EFS). They also combined the chemotherapy treatment with low dose radiation following the completion of the ABVE-PC cycles.

The treatment developed by the researchers was unique given that its focus was on early response after nine weeks, measuring to detect primary chemosensitivity – a favorable response to chemotherapy, indicating that the therapy is working. This approach differs from the traditional evaluation of the response at the end of chemotherapy. Schwartz notes that this is important, because, "This early detection allows for a reduction in therapy for those who respond well to the dose-dense treatment, and therefore, individual response can be tailored for maximum efficacy."

Schwartz, who is also a professor of pediatrics at The Warren Alpert Medical School of Brown University, believes that the study represents a new treatment model for patients with HL. She states, "Our treatment paradigm for advanced HL relied on two treatment principles: dose density enhances therapeutic efficacy and rapid early response is evidence of chemosensitivity and can serve as a basis for reduction of therapy."

The researchers conducted a trial of 216 eligible patients under 22 years of age, with intermediate or high risk HL; there were 76 females and 140 males. The median time from initial treatment to completion of the third cycle was approximately 8.7 weeks, and completion of the fifth cycle was approximately 16 weeks. While the dose densities of the chemotherapy agents exceeded those of the most commonly used regimens, cumulative doses of the chemotherapy were significantly lower, particularly in those with RER. The study was conducted at Children's Oncology Group sites between 1997 and 2001.

Schwartz says, "The results of the study indicate that through this new chemotherapy treatment we have been able to effectively deliver dose-dense chemotherapy while reducing the cumulative exposure to our patients." There are other, more immediate outcomes of the new treatment paradigm that are also of note. Schwartz also adds, "Our patients truly appreciate the rapidity of treatment. Regimens traditionally used for intermediate and advanced disease require six to eight months of chemotherapy, instead of two to three and a half months. A major benefit of this new approach is that children and young adults are able to more quickly return to school and work."

Of the 216 eligible patients, 209 were able to be evaluated for response. Of those patients, 63 percent (132 patients) showed RER, and only two of the patients showed evidence of progressive disease. RER was achieved in 67 percent of intermediate HL patients and 61 percent of high risk HL patients. The five-year event-free survival for intermediate risk HL patients was 84 percent and 85 percent for high risk HL patients. Few relapses occurred beyond three years after enrollment.

Schwartz concludes, "We have successfully achieved five-year event free survival in 84 percent of the patients and overall survival in 95 percent of our patients with this dose-dense, early-response based treatment algorithm. Only nine weeks of chemotherapy were required in 63 percent of our patients. This study has shown conclusively that the new chemotherapeutic treatment of ABVE-PC simultaneously provides high efficacy and reduces the cumulative doses of chemotherapy and radiation. We believe this represents a significant advance in the treatment of HL."

Other researchers involved in the study with Schwartz include Louis S. Constine of the University of Rochester Medical Center in Rochester, NY; Doojduen Villaluna of Children's Oncology Group - Operations Center in Arcadia, CA; Wendy B. London of Children's Oncology Group – Statistics and Data Center, University of Florida in Gainesville, FL; Robert E. Hutchison of SUNY Upstate Medical University in Syracuse, NY; Richard Sposto of Children's Hospital Los Angeles in Los Angeles CA; Steven E. Lipshultz of University of Miami Miller School of Medicine in Miami, FL; Charles S. Turner of Wake Forest University School of Medicine in Winston-Salem, NC; Pedro A. deAlarcon of St. Jude Midwest Affiliate in Peoria, IL; and Allen Chauvenet of West Virginia University HSC in Charleston, WV.

http://www.sciencedaily.com/releases/2009/07/090713160521.htm




Headlines


»Ebola virus disease update - west Africa
Between 17 and 18 August 2014, a total of 221 new cases of Ebola virus disease (laboratory-confirmed ...
»Ebola virus disease update - West Africa
Between 14 and 16 August 2014, a total of 113 new cases of Ebola virus disease (laboratory-confirmed ...
»Ebola virus disease update - west Africa
Between 12 and 13 August 2014, a total of 152 new cases of Ebola virus disease (laboratory-confirmed ...
»Ebola virus disease update - west Africa
Between 10 and 11 August 2014, a total of 128 new cases of Ebola virus disease (EVD) (laboratory-con ...


Date published: Thu, 21 Aug 2014 10:00:55
Details

»Ebola situation in Nigeria and Guinea: encouraging signs
The outbreak of Ebola virus disease in west Africa continues to evolve, with cases confirmed in Guin ...
»Statement on travel and transport in relation to Ebola virus disease (EVD) outbreak
The current Ebola virus disease (EVD) outbreak is believed to have begun in Guinea in December 2013. ...
»World Humanitarian Day: WHO calls for protection of health workers in conflicts, disasters
As major emergencies around the globe increase in scale, complexity and frequency, WHO is calling fo ...
»Ebola: Experimental therapies and rumoured remedies
The scale, duration, and lethality of the Ebola outbreak have generated a high level of public fear ...


Date published: Thu, 21 Aug 2014 10:02:27
Details

»CVD Burden Declining in Europe, Country Disparities RemainCVD Burden Declining in Europe, Country Disparities Remain
Over the past 10 years, mortality rates from CAD and stroke have dropped substantially in most of 53 ...
»New RSV Drug Reduced Viral Activity in Healthy Adults‏New RSV Drug Reduced Viral Activity in Healthy Adults‏
In a double-blind, placebo-controlled study, treatment with GS-5806, an oral RSV entry inhibitor, re ...
»Botox Prevents Development, Spread of Gastric CancerBotox Prevents Development, Spread of Gastric Cancer
Denervation of the stomach, through surgery or botulinum toxin (Botox) injections, blocks the signal ...
»MDR-TB: Bedaquiline Has Better Cure Rate, but More DeathsMDR-TB: Bedaquiline Has Better Cure Rate, but More Deaths
Resuts of a multinational randomized controlled trial have suggested that bedaquiline has a better c ...


Date published: not known
Details

»Exercise and Your Heart
Source: HealthDay - Related MedlinePlus Pages: Atrial Fibrillation, Exercise and Physical Fitness, ...
»Red Cross Offers Safety Tips for When the Kids Are Home Alone
Source: American Red Cross Related MedlinePlus Page: School Health
»Blood Transfusions May Cut Risk of 'Silent' Stroke in Kids with Sickle Cell
Study found children who got monthly infusions were less likely to suffer another attack Source: He ...
»Exercise May Guard Against Irregular Heartbeat in Older Women
Study found it lowered risk even if they were obese Source: HealthDay Related MedlinePlus Pages: Ar ...


Date published: Thu, 21 Aug 2014 10:06:15 EDT
Details

»Deadline to clear up health law eligibility near
WASHINGTON (AP) — The clock is ticking for hundreds of thousands of people who have unresolved issue ...
»Ebola: Questions, answers about an unproven drug
WASHINGTON (AP) — An experimental Ebola drug has been used to treat two American aid workers and a S ...
»Texas abortion law could send women across borders
EL PASO, Texas (AP) — Crossing borders is a part of life in El Paso in far West Texas, where people ...
»U.S. aid worker has left hospital after Ebola recovery: group
(Reuters) - U.S. aid worker Nancy Writebol has been discharged from Emory University Hospital in Atl ...


Date published: not known
Details